APA (7th ed.) Citation

McCrimmon, R. J., Palmer, K., Alsaleh, A. J. O., Lew, E., & Puttanna, A. (2022). Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in Patients with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the UK. Diabetes Therapy, 13(6), 1203. https://doi.org/10.1007/s13300-022-01267-3

Chicago Style (17th ed.) Citation

McCrimmon, Rory J., Karen Palmer, Abdul Jabbar Omar Alsaleh, Elisheva Lew, and Amar Puttanna. "Cost-Effectiveness of IGlarLixi Versus Premix BIAsp 30 in Patients with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the UK." Diabetes Therapy 13, no. 6 (2022): 1203. https://doi.org/10.1007/s13300-022-01267-3.

MLA (9th ed.) Citation

McCrimmon, Rory J., et al. "Cost-Effectiveness of IGlarLixi Versus Premix BIAsp 30 in Patients with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the UK." Diabetes Therapy, vol. 13, no. 6, 2022, p. 1203, https://doi.org/10.1007/s13300-022-01267-3.